learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
2 / 2 resultslearn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
Research
5 / 14 results
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research Hypothyroidism in Polycystic Ovarian Syndrome: A Comparative Study of Clinical Characteristics, Metabolic and Hormonal Parameters in Euthyroid and Hypothyroid Polycystic Ovarian Syndrome Women
Hypothyroidism may worsen metabolic problems like insulin resistance and obesity in women with PCOS.
research Physiological Functions of PP2A: Lessons from Genetically Modified Mice
Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.
research What Women Want: Quantifying the Perception of Hair Amount - An Analysis of Hair Diameter and Density Changes with Age in Caucasian Women
Caucasian women's hair appears thickest in their 20s, with perceived thinning after mid-30s due to both decreasing density and diameter.
research Elucidating the Roles of Three β-Glucuronosyltransferases Acting on Arabinogalactan-Proteins Using a CRISPR-Cas9 Multiplexing Approach in Arabidopsis
The study concluded that three enzymes are important for plant development by affecting sugar composition and calcium binding in plants.
Community Join
5 / 212 resultscommunity gt20029 any u-lab order possible?
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community Breaking hair loss news! GT20029 is a resounding success!
GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community GT20029 phase II results release date?
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.